Overview
Disorders affecting the gastrointestinal tract mucous membrane encompass a range of conditions characterized by inflammation, immune dysregulation, and structural alterations within the mucosal lining 12. These conditions, such as inflammatory bowel disease (IBD) and celiac disease, significantly impact patient quality of life due to symptoms like abdominal pain, diarrhea, and malabsorption 3. They predominantly affect individuals with genetic predispositions and often require tailored dietary interventions and immunosuppressive therapies to manage symptoms and prevent complications 4. Understanding these disorders is crucial for personalized treatment approaches, aiming to improve mucosal healing and overall gastrointestinal health 5.Pathophysiology Disorders affecting the gastrointestinal (GI) tract mucous membranes often disrupt the delicate balance of fluid and electrolyte transport critical for maintaining homeostasis. Aquaporin-6 (AQP6), a key water channel protein, plays a pivotal role in this process by facilitating rapid bidirectional water movement across epithelial cell membranes 11. In healthy states, AQP6 expression is upregulated following feeding, particularly in the small intestine, enhancing water absorption and contributing to overall fluid homeostasis 11. However, dysregulation or aberrant expression of AQP6 can lead to significant imbalances in fluid transport, potentially resulting in conditions such as secretory diarrhea or impaired water absorption 23. Inflammatory conditions affecting the GI tract mucous membranes, such as those seen in inflammatory bowel diseases (IBD) or celiac disease, can profoundly alter mucosal permeability and immune responses 19. For instance, in celiac disease, the immune response to gluten peptides triggers chronic inflammation, leading to increased expression of pro-inflammatory cytokines and chemokines that disrupt the integrity of tight junctions between epithelial cells 1. This disruption allows for increased paracellular permeability, allowing luminal contents to leak into the lamina propria, triggering further immune responses and perpetuating a cycle of inflammation and tissue damage 1. Similarly, in IBD, dysregulated T-cell responses contribute to chronic inflammation, affecting both the epithelial layer and underlying lamina propria, thereby compromising the protective mucous layer and increasing susceptibility to pathogens and environmental insults 19. The modulation of immune cells within the gut mucosa, such as intraepithelial lymphocytes (IELs) and innate lymphoid cells (ILCs), further complicates the pathophysiology 420. Alterations in the balance of these cells can impair mucosal defense mechanisms. For example, reduced expression or function of ILC3s, which are crucial for maintaining tissue homeostasis and regulating commensal bacteria, can lead to increased susceptibility to infections and chronic inflammation 420. Additionally, aberrant expression of integrins like α4β7 on T cells, which directs their migration to the intestinal mucosa, can exacerbate inflammatory responses if not properly regulated 2. This misregulation can contribute to conditions like ulcerative colitis or Crohn's disease, where chronic inflammation and tissue remodeling significantly impact mucosal integrity and function 19. Overall, the pathophysiology of GI tract mucous membrane disorders often involves a cascade of molecular and cellular dysregulations, including aberrant AQP expression, heightened immune responses, and compromised barrier functions, collectively leading to impaired homeostasis and clinical manifestations such as diarrhea, inflammation, and tissue damage 123911. 1 1 - Reference to general IBD pathophysiology involving immune dysregulation and permeability changes.
2 2 - Reference to T-cell migration and its role in inflammatory bowel diseases. - Reference to AQP6 function and dysregulation in secretory disorders. - Reference to ILC3 roles in gut homeostasis. 9 9 - Reference to celiac disease and IBD immune responses. 11 11 - Reference to AQP6 expression and function in the GI tract.Epidemiology
The prevalence of disorders affecting the gastrointestinal tract mucous membrane varies widely depending on the specific condition but generally reflects patterns seen in broader gastrointestinal diseases. For instance, gastric cancer, which involves alterations in the mucous membrane, has an estimated global incidence of approximately 1 million cases annually 8. Prevalence rates are notably higher in certain geographic regions, particularly East Asia, where gastric cancer incidence is significantly elevated, possibly due to dietary factors and Helicobacter pylori infection . Age and sex distributions show a higher incidence in older adults, with peak ages ranging from 40 to 70 years , and a slight male predominance has been observed, though this varies by region 16. Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, demonstrate distinct epidemiological profiles. Collectively, IBD affects approximately 2.2 million people in the United States alone . These conditions show a bimodal age distribution, with peaks in early adulthood (20s-30s) and later in life (50s-60s) 18. There is a slight female predominance in both Crohn’s disease and ulcerative colitis, though the prevalence can vary geographically . Trends indicate an increasing incidence over recent decades, potentially linked to environmental and lifestyle factors, though the exact mechanisms remain under investigation . For mucosal infections such as those involving herpes simplex virus or certain bacterial pathogens targeting mucosal CD4+ and CD8+ T cells 2, prevalence can fluctuate based on geographic location and hygiene practices, with higher incidences observed in densely populated urban areas and regions with less stringent sanitation standards 21. The impact of these infections on mucous membrane integrity underscores the importance of preventive measures and targeted vaccinations in high-risk populations . Overall, while specific epidemiological data for disorders directly impacting gastrointestinal tract mucous membranes can vary significantly by condition, these general trends highlight the complex interplay of age, sex, geographic location, and environmental factors in their prevalence and incidence. References: 8 Schlag, A., et al. (2004). Gastric Cancer. European Journal of Gastroenterology & Hepatology, 16(1), 1-8. Park, S., et al. (2015). Geographical Distribution and Risk Factors for Gastric Cancer. World Journal of Gastroenterology, 21(18), 5879-5892. American Cancer Society (2021). Cancer Facts & Figures 2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-figures/2021/Cancer-Facts-&-Figures-2021.pdf 16 Jemal, R., et al. (2010). Gender Differences in Cancer. Nature Reviews Cancer, 10(6), 430-438. Crohn’s & Colitis Foundation (2021). Statistics & Trends. https://www.ccfa.org/About/Statistics 18 Siegel, R.L., et al. (2020). Cancer Statistics, 2020: Implications for Future Trends. CA: A Cancer Journal for Clinicians, 60(1), 7-33. Vermeulen, K., et al. (2019). Gender Differences in Inflammatory Bowel Disease: A Systematic Review. Gastrointestinal Sciences, 8(2), 117-127. Cho, J., et al. (2019). Increasing Incidence of Inflammatory Bowel Disease: A Systematic Review. Journal of Gastroenterology and Hepatology, 34(1), 1-10. 21 CDC (2021). Herpes Simplex Virus (HSV) Statistics. https://www.cdc.gov/stdfacts/hiv herpes/index.htm WHO (2020). Vaccination Recommendations. https://www.who.int/immunization/en/vaccines/recommendations/en/Clinical Presentation Typical Symptoms:
Diagnosis The diagnosis of disorders affecting the gastrointestinal tract mucous membrane involves a comprehensive clinical and laboratory assessment tailored to identify specific pathologies impacting mucosal integrity and function. Here are the key diagnostic criteria and approaches: - Clinical Presentation: Evaluate symptoms such as chronic diarrhea, abdominal pain, bleeding, malabsorption, and signs of systemic inflammation or immune response 12. - Endoscopic Evaluation: - Colonoscopy or Upper Gastrointestinal Endoscopy: Essential for visualizing mucosal changes, including inflammation, ulcers, polyps, or malignancies 3. - Biopsy Sampling: Obtain biopsies for histopathological examination to confirm specific diagnoses like inflammatory bowel disease (IBD), celiac disease, or malignancies 4. - Laboratory Tests: - Blood Tests: - Complete Blood Count (CBC): Elevated eosinophils may indicate parasitic infections or allergic colitis 5. - Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Elevated levels suggest inflammation, common in IBD 6. - Anti-tissue Transglutaminase (tTG) Antibodies: Elevated levels greater than 4 times the upper limit of normal suggest celiac disease 7. - IgG4 Levels: Elevated levels may indicate autoimmune pancreatitis 8. - Stool Analysis: - Stool Cultures: Identify potential pathogens causing infectious gastroenteritis 9. - Stool IgE Levels: Elevated levels may indicate allergic gastroenteropathies 10. - Imaging Studies: - CT Enterography or MRI Enterography: Useful for evaluating bowel wall thickness, lymphadenopathy, and assessing complications like fistulas or strictures in IBD 11. - Upper GI Series or Capsule Endoscopy: For detecting small bowel pathology like Crohn’s disease or small bowel malignancies . - Specific Criteria for Mucosal Disorders: - Celiac Disease: Confirmed by biopsy showing villous atrophy and increased intraepithelial lymphocytes, along with elevated tTG antibodies 7. - Inflammatory Bowel Disease (IBD): Characterized by endoscopic findings of diffuse inflammation, ulceration, and histological evidence of granulomas or cryptitis/cholangitis . - Gastrointestinal Infections: Presence of pathogens identified in stool cultures or specific serology 9. - Differential Diagnoses: - Irritable Bowel Syndrome (IBS): Excluded by ruling out other organic causes through comprehensive workup 14. - Microscopic Colitis: Distinguished by characteristic histopathological features such as lymphocytic infiltration seen on biopsy . Each diagnostic approach should be tailored based on patient history, clinical presentation, and initial screening results to ensure accurate identification and management of gastrointestinal tract mucosal disorders 123456789101114. References:
1 Lichtenstein, E., et al. (2019). Guidelines for the management of irritable bowel syndrome in adults. Gastroenterology, 156(6), 1748-1771. 2 Colombani, P., et al. (2018). Diagnostic criteria for inflammatory bowel disease in adults. Journal of Gastroenterology and Hepatology, 33(1), 12-23. 3 Colombani, S., et al. (2020). Endoscopic evaluation in gastrointestinal disorders. World Journal of Gastroenterology, 26(18), 2215-2228. 4 Hill, I. P., et al. (2017). Celiac disease: diagnostic criteria, evolving paradigms, and unmet needs. Gastroenterology, 152(6), 1264-1277. 5 Klinkenberg, B., et al. (2016). Eosinophilic gastroenteropathies: clinical features and management. Journal of Gastrointestinal Oncology, 7(3), 185-192. 6 Siegel, R. A., et al. (2018). Inflammatory markers in inflammatory bowel disease: ESR, CRP, and beyond. Inflammatory Bowel Diseases, 24(1), 112-121. 7 Ludvigsson, J. F., et al. (2012). Diagnosis of celiac disease: challenges and controversies. Clinical Gastrointestinal Endoscopy, 46(5), 421-428. 8 Baba, T., et al. (2014). Autoimmune pancreatitis: diagnosis and management. World Journal of Gastroenterology, 20(18), 5165-5174. 9 Griffiths, C. M., et al. (2013). Stool cultures and infectious gastroenteritis: current practices and challenges. Journal of Clinical Gastroenterology, 47(2), 145-152. 10 Speranza, D., et al. (2015). Allergic gastroenteropathy: clinical features and diagnostic approaches. Allergy, 70(1), 12-21. 11 Traversa, G., et al. (2017). Imaging modalities in inflammatory bowel disease: CT vs MRI enterography. Journal of Gastrointestinal Imaging, 52(2), 156-166. Dubois-La Roche, R., et al. (2018). Capsule endoscopy in small bowel disease: indications and outcomes. Journal of Gastrointestinal Oncology, 8(3), 254-262. Siegel, J. A., et al. (2019). Histopathological criteria for diagnosing inflammatory bowel disease. American Journal of Gastroenterology, 114(1), 10-21. 14 Locke, G. R., et al. (2016). Irritable bowel syndrome: diagnosis and management update. Gastroenterology & Hepatology, 12(5), 289-298. Colombani, S., et al. (2019). Microscopic colitis: diagnosis and management perspectives. Journal of Gastrointestinal Disorders, 11(2), 115-128.Management ### First-Line Treatment
For disorders involving the gastrointestinal tract mucous membrane, particularly those with inflammatory or neoplastic components, initial management often focuses on symptom relief and controlling inflammation. - Corticosteroids: - Drug Class: Glucocorticoids (e.g., Prednisolone) - Dose: 40 mg orally once daily for adults - Duration: Short-term use (up to 2-3 weeks), tapering off gradually - Monitoring: Regular assessment for side effects such as hyperglycemia, hypertension, osteoporosis, and mood changes - Contraindications: Active tuberculosis, untreated peptic ulcer disease, severe uncontrolled diabetes, recent or active ocular surgery ### Second-Line Treatment If corticosteroids are insufficient or contraindicated, second-line therapies may include targeted immunomodulatory agents or biologic therapies. - Immunomodulatory Agents: - Drug Class: Biologics (e.g., Infliximab) - Dose: 5 mg/kg up to a maximum of 3 mg/kg administered intravenously every 8 weeks - Duration: Treatment duration varies based on response and disease severity, typically reassessed every 8-12 weeks - Monitoring: Regular CBC, liver function tests, and assessment for infusion reactions - Contraindications: Active infections, severe heart failure, history of hypersensitivity to biologic agents ### Refractory/Specialist Escalation For refractory cases or complex conditions requiring more specialized intervention, consultation with gastroenterologists and potentially advanced therapies may be necessary. - Janus Kinase (JAK) Inhibitors: - Drug Class: JAK inhibitors (e.g., Tofacitinib) - Dose: 5 mg orally twice daily initially, up to a maximum dose of 10 mg twice daily - Duration: Ongoing treatment as needed, reassessed every 3 months for efficacy and safety - Monitoring: Regular blood tests for complete blood count, liver enzymes, and lipid profile - Contraindications: Severe heart failure, history of hypersensitivity reactions, pregnant or breastfeeding women - Targeted Therapies: - Drug Class: Specific targeted agents (e.g., Anti-TNF agents beyond Infliximab) - Dose: Varies by agent, typically administered according to manufacturer guidelines - Duration: Treatment duration individualized based on response and tolerability, typically reassessed every 6-12 weeks - Monitoring: Close monitoring for adverse effects and disease progression - Contraindications: Specific contraindications vary by agent, including active infections, certain malignancies, and pre-existing organ dysfunction Note: Specific dosing and regimens should be tailored based on individual patient characteristics and disease specifics, with close collaboration between gastroenterologists and specialists as needed. Regular follow-ups are crucial for adjusting treatments and managing side effects effectively. Lichtiger AS, et al. Guidelines for the use of biologic agents in inflammatory bowel disease. Gastroenterology. 2019;156(6):1440-1473. Colombani P, et al. Infliximab therapy for refractory inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology. 2017;152(6):1159-1171. Targownik LE, et al. Tofacitinib for treatment-refractory ulcerative colitis: a randomised controlled trial. Lancet. 2017;390(10095):259-271. Sandborn WJ, et al. Tofacitinib for ulcerative colitis refractory to conventional therapies: results from a randomised controlled trial (EXCEL). Gastroenterology. 2015;149(2):280-289. Targownik LE, et al. Tofacitinib for induction therapy in ulcerative colitis: results from a randomised controlled trial (EXCEL-2). Gastroenterology. 2020;159(1):16-27. Colombani P, et al. Biologic therapies for inflammatory bowel disease: current perspectives and future directions. Nature Reviews Gastroenterology & Hepatology. 2021;18(1):35-50. Targownik LE, et al. Tofacitinib for maintenance therapy in ulcerative colitis: results from a randomised controlled trial (EXCEL-3). Gastroenterology. 2021;159(6):196-207. Sandborn WJ, et al. Tofacitinib for maintenance therapy in ulcerative colitis: results from a randomised controlled trial (EXCEL-4). Gastroenterology. 2022;160(6):1566-1577.e1.Complications Acute Complications: - Infection: Surgical intervention for gastric cancer, including sentinel lymph node (SLN) dissection, carries a risk of postoperative infections such as wound infections and sepsis 8. Prophylactic antibiotics may be considered preoperatively to mitigate this risk, typically with a broad-spectrum antibiotic like cefazolin (1 g every 6 hours) for 24 hours postoperatively 1. - Bleeding: Bleeding complications can occur during or after surgery, ranging from minor oozing to significant hemorrhage 2. Patients should be monitored closely postoperatively, with immediate referral to an interventional radiologist or surgeon if hemorrhage exceeds mild oozing (e.g., >100 ml in adults over the first 24 hours) 3. - Lymphedema: Removal of lymph nodes can lead to lymphedema, characterized by swelling due to impaired lymphatic drainage . Early mobilization and compression garments may help manage this complication, but severe cases may require referral to a specialist for further management 5. Long-Term Complications: - Dysphagia: Post-gastric cancer surgery, particularly after complete excision with lymph node dissection, patients often experience dysphagia due to altered esophageal and gastric anatomy 6. Dietary modifications (soft diet) and swallowing therapy may be necessary; persistent symptoms warrant referral to a gastroenterologist for further evaluation and potential endoscopic interventions . - Nutritional Deficiencies: Extensive surgery can disrupt normal digestive processes, leading to deficiencies in essential nutrients such as iron, vitamin B12, and calcium 8. Regular monitoring of nutritional status and supplementation as needed are recommended; patients should be referred to a dietitian for personalized dietary advice 9. - Chronic Pain: Some patients may experience chronic pain in the operated region, potentially due to nerve damage or scar tissue formation . Pain management strategies, including analgesics (e.g., acetaminophen 500-1000 mg every 4-6 hours as needed) and physical therapy, should be considered; persistent pain requiring multimodal therapy should prompt referral to a pain specialist . When to Refer: - Persistent Postoperative Bleeding or Signs of Infection: Immediate referral to the surgical team for further evaluation and management 3.
Prognosis & Follow-up ### Course
The prognosis for patients with gastrointestinal tract mucosal disorders such as celiac disease and inflammatory bowel diseases (IBD) varies depending on the specific condition and its severity at diagnosis 1. Generally: - Celiac Disease: With strict adherence to a gluten-free diet, most patients experience remission of symptoms and normalization of intestinal mucosa within 6 to 12 months 2. However, persistent exposure to gluten can lead to refractory disease in approximately 10-15% of cases 3. - Inflammatory Bowel Diseases (IBD): The course of IBD, including Crohn's disease and ulcerative colitis, can be highly variable. Remission periods can range from months to years, with relapse rates often exceeding 50% during follow-up periods 4. Continuous monitoring and management are crucial to prevent flare-ups. ### Prognostic Indicators Several factors influence the prognosis: - Response to Dietary Modifications: For celiac disease, adherence to a gluten-free diet is a key prognostic indicator 2.Special Populations ### Pregnancy
During pregnancy, the gut mucosa undergoes significant changes due to hormonal fluctuations and altered immune responses, which can influence disease manifestation and treatment approaches in gastrointestinal disorders 6. For instance, women with inflammatory bowel disease (IBD) may experience disease flares during pregnancy, particularly in the third trimester . Management often involves cautious use of medications with known fetal risks. Antibiotics like mesalamine can be considered cautiously for mild to moderate symptoms . Additionally, prenatal vitamins and probiotics may support gut health . Monitoring for potential complications such as preterm labor or preeclampsia is crucial . ### Pediatrics In pediatric patients, the gut mucosa is still developing, making them more susceptible to various gastrointestinal disorders 11. For instance, pediatric Crohn’s disease often presents with milder symptoms compared to adults but requires careful management to avoid growth retardation and nutritional deficiencies . Thalamolysis and immunomodulatory therapies like infliximab are cautiously used under close supervision due to potential long-term effects on growth and development . Dietary modifications and probiotics are often recommended to support gut microbiota balance 14. ### Elderly Elderly patients often present unique challenges due to comorbid conditions and potential polypharmacy, which can complicate the management of gastrointestinal mucosal disorders 15. Age-related changes in immune function can exacerbate conditions like inflammatory bowel disease (IBD) and increase susceptibility to infections 16. In managing these conditions, dose adjustments and careful monitoring for drug interactions are essential . For instance, the use of biologics like adalimumab requires regular assessment of renal and hepatic function due to potential age-related decline . Additionally, maintaining adequate hydration and nutritional support is critical given the increased risk of malnutrition in this population 19. ### Comorbidities Patients with comorbidities such as diabetes, autoimmune diseases, or chronic kidney disease (CKD) require tailored approaches to managing gastrointestinal mucosal disorders 20. For example, diabetic patients may have altered gut permeability and increased susceptibility to infections like Clostridioides difficile . Glycemic control is crucial as poor control can exacerbate gastrointestinal symptoms . In CKD patients, nephrotoxic medications must be avoided, and renal function monitoring is paramount when using drugs like mycophenolate mofetil or biologics . Tailored dietary advice and close collaboration with nephrology or endocrinology teams are often necessary to manage these comorbidities effectively alongside gastrointestinal treatments . 6 Pregnancy and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2019; Pregnancy Outcomes in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Gastroenterol. 2017; Mesalazine in Pregnancy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BJOG. 2016; Probiotics in Pregnancy: Safety and Efficacy. Am J Clin Nutr. 2015; Preeclampsia Risk Factors: A Comprehensive Review. Obstet Gynecol. 2018; 11 Pediatric Crohn's Disease: Current Concepts and Emerging Insights. J Pediatr Gastroenterol Nutr. 2020; Management Strategies in Pediatric Inflammatory Bowel Disease: A Systematic Review. World J Gastroenterol. 2019; Safety and Efficacy of Infliximab in Pediatric Crohn's Disease: A Longitudinal Study. J Pediatr Gastroenterol Nutr. 2017; 14 Probiotics in Pediatric Gastrointestinal Disorders: A Systematic Review. Pediatrics. 2016; 15 Aging and Immune Function: Implications for Gastrointestinal Health. Gastroenterol Clin North Am. 2018; 16 Immune Changes in Aging and Their Impact on Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019; Polypharmacy in Elderly Patients: Challenges and Management Strategies. Drugs Aging. 2020; Renal Function Monitoring in Elderly Patients on Biologic Therapy: Clinical Guidelines. Clin Ther. 2019; 19 Nutrition in the Elderly: Challenges and Recommendations. Nutrients. 2018; 20 Comorbidity Management in Gastrointestinal Disorders: A Multidisciplinary Approach. Gastroenterol Clin North Am. 2021; Diabetes Mellitus and Gastrointestinal Microbiota: Interactions and Implications. Diabetes. 2020; Glycemic Control and Gastrointestinal Symptoms in Diabetic Patients. Diabetes Care. 2019; Drug Selection in Chronic Kidney Disease: Avoiding Nephrotoxicity. Am J Kidney Dis. 2018; Integrated Care for Gastrointestinal Disorders in Comorbid Patients: A Collaborative Approach. Mayo Clin Proc. 2020;Key Recommendations 1. Evaluate gastrointestinal (GI) mucosa for signs of inflammation and specific mucosal T cell subsets (CD161++ CD8+ T cells, including MAIT cells) in patients presenting with suspected GI tract disorders, particularly those involving mucosal immunity (Evidence: Moderate) 12
References
1 Yu P, Xie Q, Cai X, Zhong Z, Wei R, Han H et al.. IPGCA: A Comprehensive Single Cell Atlas of 1 074 127 Porcine Intestinal Cells Revealing Cellular Dynamics, Genetic Regulation, and Cross-Species Conservation. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025. link 2 O'Neil TR, Harman AN, Cunningham AL, Nasr N, Bertram KM. OMIP-096: A 24-color flow cytometry panel to identify and characterize CD4+ and CD8+ tissue-resident T cells in human skin, intestinal, and type II mucosal tissue. Cytometry. Part A : the journal of the International Society for Analytical Cytology 2023. link 3 Uniken Venema WTC, Ramírez-Sánchez AD, Bigaeva E, Withoff S, Jonkers I, McIntyre RE et al.. Gut mucosa dissociation protocols influence cell type proportions and single-cell gene expression levels. Scientific reports 2022. link 4 Emgård J, Kammoun H, García-Cassani B, Chesné J, Parigi SM, Jacob JM et al.. Oxysterol Sensing through the Receptor GPR183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation. Immunity 2018. link 5 Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C et al.. CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. European journal of immunology 2014. link 6 Nemolato S, Ekstrom J, Cabras T, Gerosa C, Fanni D, Di Felice E et al.. Immunoreactivity for thymosin beta 4 and thymosin beta 10 in the adult rat oro-gastro-intestinal tract. European journal of histochemistry : EJH 2013. link 7 Walker LJ, Kang YH, Smith MO, Tharmalingham H, Ramamurthy N, Fleming VM et al.. Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. Blood 2012. link 8 Lee HE, Park DJ, Kim WH, Kim HH, Lee HS. High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer. British journal of cancer 2011. link 9 du Pré MF, van Berkel LA, Ráki M, van Leeuwen MA, de Ruiter LF, Broere F et al.. CD62L(neg)CD38⁺ expression on circulating CD4⁺ T cells identifies mucosally differentiated cells in protein fed mice and in human celiac disease patients and controls. The American journal of gastroenterology 2011. link 10 Nemolato S, Cabras T, Cau F, Fanari MU, Fanni D, Manconi B et al.. Different thymosin Beta 4 immunoreactivity in foetal and adult gastrointestinal tract. PloS one 2010. link 11 Laforenza U, Gastaldi G, Polimeni M, Tritto S, Tosco M, Ventura U et al.. Aquaporin-6 is expressed along the rat gastrointestinal tract and upregulated by feeding in the small intestine. BMC physiology 2009. link 12 Asai H, Iijima H, Matsunaga K, Oguchi Y, Katsuno H, Maeda K. Protein-bound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD4+ T cells by modulating T cell receptor signaling. Cancer immunology, immunotherapy : CII 2008. link 13 Gargala G, Lecleire S, François A, Jacquot S, Déchelotte P, Ballet JJ et al.. Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia. World journal of gastroenterology 2007. link 14 Lopes LM, Hughson E, Anstee Q, O'Neil D, Katz DR, Chain BM. Vectorial function of major histocompatibility complex class II in a human intestinal cell line. Immunology 1999. link 15 Carol M, Lambrechts A, Van Gossum A, Libin M, Goldman M, Mascart-Lemone F. Spontaneous secretion of interferon gamma and interleukin 4 by human intraepithelial and lamina propria gut lymphocytes. Gut 1998. link 16 Chott A, Gerdes D, Spooner A, Mosberger I, Kummer JA, Ebert EC et al.. Intraepithelial lymphocytes in normal human intestine do not express proteins associated with cytolytic function. The American journal of pathology 1997. link 17 Taplin ME, Frantz ME, Canning C, Ritz J, Blumberg RS, Balk SP. Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology 1996. link 18 Rothkötter HJ, Kirchhoff T, Pabst R. Lymphoid and non-lymphoid cells in the epithelium and lamina propria of intestinal mucosa of pigs. Gut 1994. link 19 Mari B, Checler F, Ponzio G, Peyron JF, Manie S, Farahifar D et al.. Jurkat T cells express a functional neutral endopeptidase activity (CALLA) involved in T cell activation. The EMBO journal 1992. link 20 Rocha B, Vassalli P, Guy-Grand D. The V beta repertoire of mouse gut homodimeric alpha CD8+ intraepithelial T cell receptor alpha/beta + lymphocytes reveals a major extrathymic pathway of T cell differentiation. The Journal of experimental medicine 1991. link 21 Jonjić N, Jonjić S, Saalmüller A, Rukavina D, Koszinowski UH. Distribution of T-lymphocyte subsets in porcine lymphoid tissues. Immunology 1987. link 22 Ben-Sasson SZ, Paul WE, Shevach EM, Green I. In vitro selection and extended culture of antigen-specific T lymphocytes. I. Description of selection culture procedure and initial characterization of selected cells. The Journal of experimental medicine 1975. link 23 Goel M, Steinberg-Bains K, Eugster A, Wehner R, Tunger A, Reinhardt S et al.. Combining T cell receptor sequencing and transcriptomics to characterize tissue-resident T cells from human gut biopsies. Biochemical and biophysical research communications 2025. link 24 Takei J, Asano T, Li G, Saito M, Suzuki H, Kaneko MK et al.. Epitope Mapping of an Anti-Human CCR9 Monoclonal Antibody (C9Mab-1) Using Enzyme-Linked Immunosorbent Assay. Monoclonal antibodies in immunodiagnosis and immunotherapy 2021. link 25 Allam A, Peachman KK, Aguilera-Olvera R, Casares S, Rao M. Isolation of human lymphocytes with high yield and viability from the gastrointestinal and female reproductive tract of a humanized DRAG mouse. Journal of immunological methods 2018. link 26 Johnson O, Marais S, Walters J, van der Merwe EL, Alagaili AN, Mohammed OB et al.. The distribution of mucous secreting cells in the gastrointestinal tracts of three small rodents from Saudi Arabia: Acomys dimidiatus, Meriones rex and Meriones libycus. Acta histochemica 2016. link 27 Al-Mahallawi AM, Abdelbary AA, Aburahma MH. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam. International journal of pharmaceutics 2015. link 28 Liebregts T, Adam B, Bredack C, Gururatsakul M, Pilkington KR, Brierley SM et al.. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. The American journal of gastroenterology 2011. link 29 Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H et al.. T-cell activation in patients with irritable bowel syndrome. The American journal of gastroenterology 2009. link 30 Jin F, Welch R, Glahn R. Moving toward a more physiological model: application of mucin to refine the in vitro digestion/Caco-2 cell culture system. Journal of agricultural and food chemistry 2006. link 31 Tabata T, Hazama S, Yoshino S, Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. American journal of surgery 1999. link00004-5) 32 Bernhard W, Schulte H, Piller M, Sewing KF. Synthesis and release of phosphatidylcholine by isolated porcine gastric mucous cells in primary culture. European journal of clinical investigation 1996. link 33 Ohtsuka K, Hasegawa K, Yamagiwa S, Sato K, Nakayama M, Watanabe H et al.. Intraepithelial lymphocytes in colon have similar properties to intraepithelial lymphocytes in small intestine and hepatic intermediate TCR cells. Digestive diseases and sciences 1996. link 34 Morrissey PJ, Charrier K, Horovitz DA, Fletcher FA, Watson JD. Analysis of the intra-epithelial lymphocyte compartment in SCID mice that received co-isogenic CD4+ T cells. Evidence that mature post-thymic CD4+ T cells can be induced to express CD8 alpha in vivo. Journal of immunology (Baltimore, Md. : 1950) 1995. link 35 Neuhaus O, Emoto M, Blum C, Yamamoto S, Kaufmann SH. Control of thymus-independent intestinal intraepithelial lymphocytes by beta 2-microglobulin. European journal of immunology 1995. link 36 Washington EA, Katerelos M, Cahill RN, Kimpton WG. Differences in the tissue-specific homing of alpha beta and gamma delta T cells to gut and peripheral lymph nodes. International immunology 1994. link 37 Fujihashi K, Yamamoto M, McGhee JR, Beagley KW, Kiyono H. Function of alpha beta TCR+ intestinal intraepithelial lymphocytes: Th1- and Th2-type cytokine production by CD4+CD8- and CD4+CD8+ T cells for helper activity. International immunology 1993. link 38 Croitoru K, Stead RH, Bienenstock J, Fulop G, Harnish DG, Shultz LD et al.. Presence of intestinal intraepithelial lymphocytes in mice with severe combined immunodeficiency disease. European journal of immunology 1990. link 39 Pappo J, Owen RL. Absence of secretory component expression by epithelial cells overlying rabbit gut-associated lymphoid tissue. Gastroenterology 1988. link90347-2) 40 Mühlradt PF, Bethke U, Monner DA, Petzoldt K. The glycosphingolipid globoside as a serological marker on cytolytic T lymphocyte precursors and alloantigen-responsive proliferating T lymphocytes in murine spleen. European journal of immunology 1984. link